| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abemaciclib plus fulvestrant for breast cancer
|
Stirrups, Robert
|
|
|
20 |
11 |
p. e617
|
artikel
|
| 2 |
Cancer awareness crusades—pink ribbons and growing moustaches
|
Cacciamani, Giovanni E
|
|
|
20 |
11 |
p. 1491-1492
|
artikel
|
| 3 |
Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours?
|
Pal, Sumanta
|
|
|
20 |
11 |
p. 1473-1474
|
artikel
|
| 4 |
CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?
|
Goel, Shom
|
|
|
20 |
11 |
p. 1479-1481
|
artikel
|
| 5 |
Changes in clinical trials of cancer drugs in mainland China over the decade 2009–18: a systematic review
|
Li, Ning
|
|
|
20 |
11 |
p. e619-e626
|
artikel
|
| 6 |
Changes in e-cigarette policies worldwide
|
Burki, Talha Khan
|
|
|
20 |
11 |
p. 1487
|
artikel
|
| 7 |
Clarifications sought for implications of PORTEC-3 in clinics
|
Revannasiddaiah, Swaroop
|
|
|
20 |
11 |
p. e607
|
artikel
|
| 8 |
Complete mesocolic excision for colon cancer: is now the time for a change in practice?
|
West, Nicholas P
|
|
|
20 |
11 |
p. 1474-1476
|
artikel
|
| 9 |
Core elements of national cancer control plans: a tool to support plan development and review
|
Oar, Andrew
|
|
|
20 |
11 |
p. e645-e652
|
artikel
|
| 10 |
Correction to Lancet Oncol 2019; 20: 1602–14
|
|
|
|
20 |
11 |
p. e613
|
artikel
|
| 11 |
Correction to Lancet Oncol 2019; 20: 1506–517
|
|
|
|
20 |
11 |
p. e613
|
artikel
|
| 12 |
Correction to Lancet Oncol 2019; 20: 1286–94
|
|
|
|
20 |
11 |
p. e613
|
artikel
|
| 13 |
Correction to Lancet Oncol 2019; 20: e522–34
|
|
|
|
20 |
11 |
p. e613
|
artikel
|
| 14 |
Correction to Lancet Oncol 2019; 20: e616
|
|
|
|
20 |
11 |
p. e613
|
artikel
|
| 15 |
Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts
|
Sankaranarayanan, Rengaswamy
|
|
|
20 |
11 |
p. e637-e644
|
artikel
|
| 16 |
Developing an independent Palestinian cancer care capacity
|
Gil, Ziv
|
|
|
20 |
11 |
p. 1485-1486
|
artikel
|
| 17 |
European Society of Medical Oncology 2019 Congress
|
Lai, Cheryl
|
|
|
20 |
11 |
p. 1488
|
artikel
|
| 18 |
Gingival localisation of extramedullary multiple myeloma
|
Lombardi, Niccolò
|
|
|
20 |
11 |
p. e653
|
artikel
|
| 19 |
Global elimination of cervical cancer is achievable—with commitment
|
The Lancet Oncology,
|
|
|
20 |
11 |
p. 1467
|
artikel
|
| 20 |
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study
|
Agarwal, Neeraj
|
|
|
20 |
11 |
p. 1518-1530
|
artikel
|
| 21 |
Hyperbaric oxygen for radiation cystitis
|
Feldmeier, John J
|
|
|
20 |
11 |
p. 1481-1482
|
artikel
|
| 22 |
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
|
Brand, Douglas H
|
|
|
20 |
11 |
p. 1531-1543
|
artikel
|
| 23 |
Interventions to reduce aggressive care at end of life among patients with cancer: a systematic review
|
Abedini, Nauzley C
|
|
|
20 |
11 |
p. e627-e636
|
artikel
|
| 24 |
Maintenance chemotherapy in rhabdomyosarcoma: the new standard of care
|
Meyer, William H
|
|
|
20 |
11 |
p. 1476-1477
|
artikel
|
| 25 |
Metronomic chemotherapy option for advanced oral cancer
|
Gourd, Elizabeth
|
|
|
20 |
11 |
p. e614
|
artikel
|
| 26 |
Moonshot or groundshot: addressing Europe's cancer challenge through a patient-focused, data-enabled lens
|
Lawler, Mark
|
|
|
20 |
11 |
p. 1482-1485
|
artikel
|
| 27 |
Navigating prostate cancer control in Nigeria
|
Chidebe, Runcie C W
|
|
|
20 |
11 |
p. 1489-1491
|
artikel
|
| 28 |
Niraparib improves progression-free survival in ovarian cancer
|
Gourd, Elizabeth
|
|
|
20 |
11 |
p. e615
|
artikel
|
| 29 |
Nivolumab for previously treated squamous oesophageal carcinoma
|
Smyth, Elizabeth C
|
|
|
20 |
11 |
p. 1468-1469
|
artikel
|
| 30 |
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
|
Kato, Ken
|
|
|
20 |
11 |
p. 1506-1517
|
artikel
|
| 31 |
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial
|
Naing, Aung
|
|
|
20 |
11 |
p. 1544-1555
|
artikel
|
| 32 |
Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study
|
Arnold, Melina
|
|
|
20 |
11 |
p. 1493-1505
|
artikel
|
| 33 |
Quality of life considerations in the treatment of metastatic hormone-sensitive prostate cancer
|
Chambers, Suzanne K
|
|
|
20 |
11 |
p. 1469-1471
|
artikel
|
| 34 |
Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2–3 trial
|
Oscarsson, Nicklas
|
|
|
20 |
11 |
p. 1602-1614
|
artikel
|
| 35 |
Refining prognosis after first-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy in chronic lymphocytic leukaemia
|
Smolej, Lukáš
|
|
|
20 |
11 |
p. 1478-1479
|
artikel
|
| 36 |
Sparing of swallowing-related organs in radiotherapy for oropharyngeal squamous cell carcinoma
|
Mazzola, Rosario
|
|
|
20 |
11 |
p. e611
|
artikel
|
| 37 |
Sparing of swallowing-related organs in radiotherapy for oropharyngeal squamous cell carcinoma–Authors’ reply
|
Palma, David A
|
|
|
20 |
11 |
p. e612
|
artikel
|
| 38 |
Stereotactic beam radiotherapy for prostate cancer: is less, more?
|
Miralbell, Raymond
|
|
|
20 |
11 |
p. 1471-1472
|
artikel
|
| 39 |
Targeted therapy for BRAF-mutant colorectal cancer
|
Gunjur, Ashray
|
|
|
20 |
11 |
p. e618
|
artikel
|
| 40 |
Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study
|
Herling, Carmen D
|
|
|
20 |
11 |
p. 1576-1586
|
artikel
|
| 41 |
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial
|
Tan, Antoinette R
|
|
|
20 |
11 |
p. 1587-1601
|
artikel
|
| 42 |
Veliparib for advanced ovarian cancer
|
Burki, Talha Khan
|
|
|
20 |
11 |
p. e616
|
artikel
|
| 43 |
Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial
|
Bisogno, Gianni
|
|
|
20 |
11 |
p. 1566-1575
|
artikel
|
| 44 |
What is the best PET target for early biochemical recurrence of prostate cancer?
|
Andriole, Gerald L
|
|
|
20 |
11 |
p. e608
|
artikel
|
| 45 |
What is the best PET target for early biochemical recurrence of prostate cancer?–Authors’ reply
|
Calais, Jeremie
|
|
|
20 |
11 |
p. e609-e610
|
artikel
|
| 46 |
5-year outcome after complete mesocolic excision for right-sided colon cancer: a population-based cohort study
|
Bertelsen, Claus A
|
|
|
20 |
11 |
p. 1556-1565
|
artikel
|
Tijdschrift beschrijving